Evidence map›Paper›PMID 35008226›Full record

ArticleCancers2021

Quantification and Phenotypic Characterization of Extracellular Vesicles from Patients with Acute Myeloid and B-Cell Lymphoblastic Leukemia.

Marijana Miljkovic-Licina, Nicolas Arraud, Aicha Dorra Zahra, Patricia Ropraz, Thomas Matthes

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Extracellular vesicles in malignant and normal B lymphocyte growth and development.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marijana Miljkovic-LicinaLaboratory for R&D in Hematology, Center for Translational Research in Onco-Hematology, University of Geneva Medical School, 1206 Geneva, Switzerland.ORCID 0000-0001-9023-2208
Nicolas ArraudDepartment of Diagnostics, Clinical Pathology Service, Geneva University Hospitals, 1205 Geneva, Switzerland.
Aicha Dorra ZahraLaboratory for R&D in Hematology, Center for Translational Research in Onco-Hematology, University of Geneva Medical School, 1206 Geneva, Switzerland.
Patricia RoprazLaboratory for R&D in Hematology, Center for Translational Research in Onco-Hematology, University of Geneva Medical School, 1206 Geneva, Switzerland.
Thomas MatthesLaboratory for R&D in Hematology, Center for Translational Research in Onco-Hematology, University of Geneva Medical School, 1206 Geneva, Switzerland.
University of Geneva · CH

Funding

CSRD VA 1Dr. Henri Dubois-Ferrière Dinu Lipatti 2
6 · The paper itself

Abstract

Extracellular vesicles (EVs) act in cell-to-cell communication, delivering cargo from donor to recipient cells and modulating their physiological condition. EVs secreted by leukemic blasts in patients with leukemia have been shown to influence the fate of recipient cells in the bone marrow microenvironment. Methods to quantify and to characterize them phenotypically are therefore urgently needed to study their functional role in leukemia development and to evaluate their potential as targets for therapy. We have used cryo-electron microscopy to study morphology and size of leukemic EVs, and nanoparticle tracking analysis and fluorescence triggering flow cytometry to quantify EVs in platelet-free plasma from a small cohort of leukemia patients and healthy blood donors. Additional studies with a capture bead-based assay allowed us to establish phenotypic signatures of leukemic EVs from 17 AML and 3 B-ALL patients by evaluating the expression of 37 surface antigens. In addition to tetraspanins and lineage-specific markers we found several adhesion molecules (CD29, and CD146) to be highly expressed by EVs from B-ALL and several leukemic stem cell antigens (CD44, CD105, CD133, and SSEA-4) to be expressed by EVs from AML patients. Further improvements in analytical methods to study EVs are needed before potentially using them as biomarkers for leukemia prognosis and follow-up.

Indexed as

acute leukemiaAMLB-ALLextracellular vesiclesflow cytometry

Identifiers

PMID35008226
PMCPMC8750511
OpenAlexW4200510157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.